Ownership and insider activity for Fractyl Health, Inc. (GUTS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Price
| Price | $0.56 |
| Market Cap | $89M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-14 | BRADLEY WILLIAM | P-Purchase | 64,516 | $40K |
| 2026-06-12 | Royan Ajay | P-Purchase | 23,000 | $20K |
| 2026-06-10 | BRADLEY WILLIAM | P-Purchase | 68,493 | $50K |
| 2026-06-10 | BRADLEY WILLIAM | A-Award | 22,500 | $16K |
| 2026-06-10 | Conaway Samuel | A-Award | 22,500 | $16K |
| 2026-06-10 | Royan Ajay | A-Award | 22,500 | $16K |
| 2026-06-10 | Thompson Christopher Charles | A-Award | 22,500 | $16K |
| 2026-06-10 | Elia Marc | A-Award | 22,500 | $16K |
| 2026-06-10 | Barnes Kelly Ann | A-Award | 22,500 | $16K |
| 2026-06-10 | MEANWELL CLIVE | A-Award | 22,500 | $16K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.8M | $29.1M | $95.5M | $49.3M | $33.5M | $67.5M | $81.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | $22000 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | $73000 | $73000 | 0 |
| Total Current Assets | $6.8M | $30.9M | $96.4M | $51.6M | $35.6M | $71.8M | $87.6M |
| Property, Plant & Equipment | $2.1M | $1.4M | $1.3M | $1.6M | $30.8M | $31.4M | $29.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $863000 | $835000 | 0 | 0 |
| Total Assets | $8.9M | $34.8M | $102.5M | $61.0M | $76.2M | $108.1M | $121.4M |
| Accounts Payable | $608000 | $304000 | $970000 | $980000 | $553000 | $3.2M | $1.6M |
| Short-term Debt | 0 | $7.2M | $15.7M | 0 | $2.7M | 0 | $5.1M |
| Total Current Liabilities | $3.4M | $10.9M | $23.7M | $7.3M | $11.2M | $19.8M | $18.3M |
| Long-term Debt | $14.9M | $8.1M | $287.3M | $305.1M | $342.5M | $30.2M | $30.6M |
| Total Liabilities | $152.9M | $19.8M | $311.9M | $313.3M | $401.3M | $79.7M | $111.9M |
| Retained Earnings | -$153.9M | -$184.3M | -$223.1M | -$269.5M | -$346.6M | -$415.3M | -$556.3M |
| Total Equity | -$144.0M | $15.0M | -$209.3M | -$252.3M | -$325.1M | $28.4M | $9.5M |
| Total Debt | $14.9M | $15.3M | $304.3M | $306.8M | $373.7M | $62.5M | $61.6M |
| Net Debt | $9.1M | -$13.8M | $208.9M | $257.5M | $340.2M | -$5.0M | -$19.9M |
| Working Capital | $3.4M | $20.0M | $72.7M | $44.3M | $24.5M | $52.0M | $69.2M |
Financial Health
| Debt / Equity | -36.48 |
| Current Ratio | 3.15 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.47 |
Profitability
| Return on Equity | -1625.88% |
| Return on Invested Capital | -120.27% |
| Return on Assets | -128.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · ARTV · ATYR · BMEA · DTIL · MGX
Explore sector: Healthcare · Biotechnology
More sections of GUTS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks